JERUSALEM, Israel, Jan. 31 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals has added the accomplished Derek LeRoith, MD PhD to its world class scientific board. With contributions leading to over 500 publications, Dr. LeRoith is presently the Chief of the Division of Endocrinology and Diabetes in the Department of Medicine at the Mt. Sinai School of Medicine.
Dr. LeRoith began his studies in Cape Town, where he received both his medical degree and completed his thesis for his PhD. His career in America started as the Chief of the Diabetes Branch at the National Institute of Diabetes, Digestive and Kidney Diseases in the National Institute of Health in Maryland, and he is now serving as the Chief of the Division of Endocrinology, Diabetes and Bone Diseases. He is a prominent member in over 15 professional societies globally, including the Society for Endocrinology, Metabolism and Diabetes of South Africa, the European Association for the Study of Diabetes, and the American Diabetes Association.
Dr. LeRoith has been granted a number of prominent administrative responsibilities, including positions within the American Diabetes Association (President of the Montgomery Chapter, President of the Washington D.C. Affiliate, the Board of Directors, Chairperson of the Research and Grant Panel), Chief of the Endocrine Consulting Services at the Clinical Center of the National Institution of Health, President of the International Society for Insulin-like Growth Factor Research, and Board of Directors for the Endocrine Fellows Foundation, among many others. His awards include, but are not limited to, Medal for Physiology, the Bronte Stewart Award for PhD Thesis, British Endocrine Society Transatlantic Medal, and multiple Memorial Lectures.
CEO Nadav Kidron states, “We are proud to have Dr. Derek LeRoith join our board of directors with his vast experience amongst the influential leaders in diabetic research in the United States.” As our studies progress, this will enable Oramed Pharmaceuticals, Inc. to open doors and expand the knowledge of our technology into international territory.
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals Inc. is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website: www.oramedpharma.com
Investor Relations Contact: Oramed Pharmaceuticals, Inc. Vinisha Agnihotri(646) 467-2252 info@oramedpharma.comwww.oramedpharma.com
Oramed Pharmaceuticals, Inc.
CONTACT: Investor Relations, Vinisha Agnihotri, of Oramed Pharmaceuticals,Inc., +1-646-467-2252, or info@oramedpharma.com
Web site: http://www.oramedpharma.com/
